Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Addex Pharmaceuticals has revealed that in a clinical trial involving its ADX71943, the compound showed analgesic effects on pain. The trial involved three preclinical models of pain.
Subscribe to our email newsletter
In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum effective oral dose of 10mg/kg.
In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administration of 3 to 10mg/kg.
In the third model, an increased visceral pain threshold was seen using ADX71943 with a minimum effective dose between 3 and 10mg/kg.
The company said that the developability profile of the drug is good and it will initiate clinical trial in the fourth quarter of 2010.
Sonia Poli, head of non-clinical development at Addex, said: “We are impressed with the profile of the compound and by its activity in these models. Furthermore, minimum effective doses observed in the preclinical models and the pharmacokinetic properties of the compound support prediction of treatment regimens in humans compatible with the target patient population and disease.”
ADX71943 is an oral positive allosteric modulator (PAM) of the GABA(B) receptor, which is seen as a potential treatment for osteoarthritis pain and chronic nociceptive pain.